相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells
Shigeki Nanjo et al.
ONCOTARGET (2016)
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
Keunchil Park et al.
LANCET ONCOLOGY (2016)
High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs
Takahisa Kawamura et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: Data from Phase II studies
M. J. Ahn et al.
EUROPEAN JOURNAL OF CANCER (2015)
Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)-Pretreated Non-Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease
Petra Hoffknecht et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
James Chih-Hsin Yang et al.
LANCET ONCOLOGY (2015)
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
Jean-Charles Soria et al.
LANCET ONCOLOGY (2015)
Icotinib might be effective for the treatment of leptomeningeal carcinomatosis in non-small cell lung cancer with sensitive EGFR mutations
Lei Gong et al.
LUNG CANCER (2015)
Gefitinib and Erlotinib in Metastatic Non-Small Cell Lung Cancer: A Meta-Analysis of Toxicity and Efficacy of Randomized Clinical Trials
Mauricio Burotto et al.
ONCOLOGIST (2015)
A Phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer
David M. Jackman et al.
ONCOTARGET (2015)
Erlotinib in combination with pemetrexed/cisplatin for leptomeningeal metastases and cerebrospinal fluid drug concentrations in lung adenocarcinoma patients after gefitinib faliure
Haihong Yang et al.
TARGETED ONCOLOGY (2015)
Impact of Multimodality Approach for Patients with Leptomeningeal Metastases from Solid Tumors
Jeanny Kwon et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2014)
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Yi-Long Wu et al.
LANCET ONCOLOGY (2014)
Afatinib combined with cetuximab for lung adenocarcinoma with leptomeningeal carcinomatosis
Chou-Han Lin et al.
LUNG CANCER (2014)
Chest Wall Pain as the Presenting Symptom of Leptomeningeal Carcinomatosis
Kyoung Bo Sim et al.
ANNALS OF REHABILITATION MEDICINE-ARM (2014)
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Versus Placebo as Maintenance Therapy for Advanced Nonsmall-cell Lung Cancer: A Meta-analysis of Randomized Controlled Trials
S. Alimujiang et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2013)
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Erlotinib Versus Gefitinib for Control of Leptomeningeal Carcinomatosis in Non-Small-Cell Lung Cancer
Eunyoung Lee et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases-One with a remarkable thoracic response as well
J. L. Kuiper et al.
LUNG CANCER (2013)
Comparison of the Efficacy and Safety of EFGR Tyrosine Kinase Inhibitor Monotherapy with Standard Second-line Chemotherapy in Previously Treated Advanced Non-small-cell Lung Cancer: a Systematic Review and Meta-analysis
Wei-Xiang Qi et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2012)
Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer
Yosuke Togashi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Leptomeningeal Metastasis from Non-small Cell Lung Cancer Survival and the Impact of Whole Brain Radiotherapy
Patrick G. Morris et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: A case report and review of the literature
Yosuke Togashi et al.
LUNG CANCER (2012)
Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group
Shigeki Umemura et al.
LUNG CANCER (2012)
Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era
Jin Hyun Park et al.
LUNG CANCER (2012)
Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
Ying Yuan et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2012)
Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy
Takeshi Masuda et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation
Yosuke Togashi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation
Geoffrey R. Oxnard et al.
CLINICAL CANCER RESEARCH (2011)
High-dose Erlotinib for Refractory Brain Metastases in a Patient with Relapsed Non-small Cell Lung Cancer
Akito Hata et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou et al.
LANCET ONCOLOGY (2011)
Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations
Jenn-Yu Wu et al.
LUNG CANCER (2011)
Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: Clinical benefit with optimal patient selection
Akito Hata et al.
LUNG CANCER (2011)
Pulsatile high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer
Christian Grommes et al.
NEURO-ONCOLOGY (2011)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Development of Central Nervous System Metastases in Patients with Advanced Non-Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib
Stephanie Heon et al.
CLINICAL CANCER RESEARCH (2010)
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Prognostic factors and treatment options in patients with leptomeningeal metastases of different primary tumors: a retrospective analysis
Karin Oechsle et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2010)
High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer
Jennifer L. Clarke et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi et al.
LANCET ONCOLOGY (2010)
Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer
Kyoichi Kaira et al.
LUNG CANCER (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Carcinomatous Meningitis in Non-Small-Cell Lung Cancer: Response to High-Dose Erlotinib
Nirav Dhruva et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy of Erlotinib for Brain and Leptomeningeal Metastases in Patients with Lung Adenocarcinoma Who Showed Initial Good Response to Gefitinib
Tatsuya Katayama et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
EGFR testing in lung cancer is ready for prime time
Fred R. Hirsch et al.
LANCET ONCOLOGY (2009)
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI
Hyeon Gyu Yi et al.
LUNG CANCER (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Clinicopathologic and Molecular Features of Epidermal Growth Factor Receptor T790M Mutation and c-MET Amplification in Tyrosine Kinase Inhibitor-resistant Chinese Non-small Cell Lung Cancer
Hua-Jun Chen et al.
PATHOLOGY & ONCOLOGY RESEARCH (2009)
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor - Mutant lung adenocarcinomas with acquired resistance to kinase inhibitors
Marissa N. Balak et al.
CLINICAL CANCER RESEARCH (2006)
Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib
David M. Jackman et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Gefitinib response of erlotinib-refractory lung cancer involving meninges - role of EGFR mutation
NW Choong et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2006)
被撤回的出版物: Neoplastic meningitis (Retracted article. See vol. 28, pg 4018, 2010)
MC Chamberlain
JOURNAL OF CLINICAL ONCOLOGY (2005)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Leptomeningeal metastasis:: survival and prognostic factors in 155 patients
U Herrlinger et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2004)
Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer
K Hotta et al.
LUNG CANCER (2004)
分享论文
